The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review

Endocrine therapy (ET) is the cornerstone of the adjuvant management of luminal early breast cancer (eBC), a group of breast cancer characterized by positive expression of hormone receptors (HR+). Possible therapies include tamoxifen, aromatase inhibitors (AIs) or, in pre-menopausal patients, ovarian function suppression (OFS), achieved by surgery (oophorectomy) or by GnRH agonists [1]. For some time, five years of adjuvant ET was considered optimal, and became the standard of care for all patients [1].

Source: Cancer Treatment Reviews - January 25, 2019 Category: Cancer & Oncology Authors: Lorenzo Rossi, Amelia McCartney, Irene De Santo, Emanuela Risi, Erica Moretti, Luca Malorni, Laura Biganzoli, Angelo Di Leo Tags: Anti-Tumour Treatment Source Type: research